Literature DB >> 20533191

Viral hepatitis in Hawai'i--differing perspectives.

Alan D Tice1, Michael Bannan, Kay Bauman, Tarquin Collis, Alba Hall, William Haning, Shoshana Hannemann, C Bradley Hare, Joseph Humphry, Robert Jao, Carroll Leevy, Heather Lusk, Edward Ochoa, Neal Palafox, Nancy Withers, Kenneth Akinaka.   

Abstract

This publication contains information from a conference titled "Individual Perspectives on the Silent Epidemic of Viral Hepatitis in Hawai'i" held in October of 2007 with updates and additional contributions from annual conferences in 2008 and 2009. These conferences were sponsored by the Hepatitis Support Network of Hawai'i and held in Honolulu, Hawai'i at the Queen's Conference Center. The primary objectives of the conferences have been to heighten awareness of viral hepatitis in Hawai'i and to bring together health care professionals to learn about these infections and to help them respond to the challenges they bring to the people of Hawai'i. The initial conference was oriented to present the unique and individual perspectives of patients, physicians, and other healthcare providers specific to the complex issues of hepatitis in an effort to help them understand their role in the context of others and to develop a team approach in responding to this epidemic.

Entities:  

Mesh:

Year:  2010        PMID: 20533191      PMCID: PMC3400474     

Source DB:  PubMed          Journal:  Hawaii Med J        ISSN: 0017-8594


  44 in total

1.  Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment.

Authors:  José M Sánchez-Tapias; Moisés Diago; Pedro Escartín; Jaime Enríquez; Manuel Romero-Gómez; Rafael Bárcena; Javier Crespo; Raúl Andrade; Eva Martínez-Bauer; Ramón Pérez; Milagros Testillano; Ramón Planas; Ricard Solá; Manuel García-Bengoechea; Javier Garcia-Samaniego; Miguel Muñoz-Sánchez; Ricardo Moreno-Otero
Journal:  Gastroenterology       Date:  2006-08       Impact factor: 22.682

2.  Endemic hepatitis B virus infection and chronic liver disease mortality in the Republic of Palau, 1990-2002.

Authors:  Tara M Vogt; Susan T Goldstein; Stevenson Kuartei
Journal:  Trans R Soc Trop Med Hyg       Date:  2006-06-12       Impact factor: 2.184

3.  Hepatitis C - contamination of toothbrushes: myth or reality?

Authors:  G Lock; M Dirscherl; F Obermeier; C M Gelbmann; C Hellerbrand; A Knöll; J Schölmerich; W Jilg
Journal:  J Viral Hepat       Date:  2006-09       Impact factor: 3.728

4.  A double-blind placebo-controlled study of emtricitabine in chronic hepatitis B.

Authors:  Seng Gee Lim; Tay Meng Ng; Nelson Kung; Zahary Krastev; Miroslava Volfova; Petr Husa; Samuel S Lee; Sing Chan; Mitchell L Shiffman; Mary Kay Washington; Amy Rigney; Jane Anderson; Elsa Mondou; Andrea Snow; Jeff Sorbel; Richard Guan; Franck Rousseau
Journal:  Arch Intern Med       Date:  2006-01-09

5.  Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.

Authors:  M P Manns; J G McHutchison; S C Gordon; V K Rustgi; M Shiffman; R Reindollar; Z D Goodman; K Koury; M Ling; J K Albrecht
Journal:  Lancet       Date:  2001-09-22       Impact factor: 79.321

6.  Hepatitis C virus infection among prisoners in the California state correctional system.

Authors:  Rena K Fox; Sue L Currie; Jennifer Evans; Teresa L Wright; Leslie Tobler; Bruce Phelps; Michael P Busch; Kimberly A Page-Shafer
Journal:  Clin Infect Dis       Date:  2005-06-09       Impact factor: 9.079

Review 7.  Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins.

Authors:  J E Darnell; I M Kerr; G R Stark
Journal:  Science       Date:  1994-06-03       Impact factor: 47.728

8.  Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection.

Authors:  John G McHutchison; Gregory T Everson; Stuart C Gordon; Ira M Jacobson; Mark Sulkowski; Robert Kauffman; Lindsay McNair; John Alam; Andrew J Muir
Journal:  N Engl J Med       Date:  2009-04-30       Impact factor: 91.245

9.  Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose.

Authors:  Stephanos J Hadziyannis; Hoel Sette; Timothy R Morgan; Vijayan Balan; Moises Diago; Patrick Marcellin; Giuliano Ramadori; Henry Bodenheimer; David Bernstein; Mario Rizzetto; Stefan Zeuzem; Paul J Pockros; Amy Lin; Andrew M Ackrill
Journal:  Ann Intern Med       Date:  2004-03-02       Impact factor: 25.391

Review 10.  Treating hepatitis C in the prison population is cost-saving.

Authors:  Jennifer A Tan; Tom A Joseph; Sammy Saab
Journal:  Hepatology       Date:  2008-11       Impact factor: 17.425

View more
  1 in total

1.  Frequency of and Factors Associated with Receipt of Liver-Related Specialty Care Among Patients with Hepatitis C in the Chronic Hepatitis Cohort Study.

Authors:  Monique A Foster; Jian Xing; Anne C Moorman; Joseph Boscarino; Stuart C Gordon; Mei Lu; Loralee Rupp; Mark A Schmidt; Connie M Trinacty; Fujie Xu; Scott D Holmberg; Philip R Spradling
Journal:  Dig Dis Sci       Date:  2016-08-10       Impact factor: 3.199

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.